Summary
5.5250 -0.0350(-0.6301%)07/01/2024
Alimera Sciences Inc. (ALIM)
Alimera Sciences Inc. (ALIM)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
-0.6301 | 75.8730 | 77.5641 | 42.0513 | 42.7835 | 109.8485 | -58.5019 | -96.6424 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 5.5250 | |
Open | 5.5500 | |
High | 5.5500 | |
Low | 5.5200 | |
Volume | 166,410 | |
Change | -0.0350 | |
Change % | -0.6301 | |
Avg Volume (20 Days) | 933,959 | |
Volume/Avg Volume (20 Days) Ratio | 0.18 | |
52 Week Range | 2.60 - 5.65 | |
Price vs 52 Week High | -2.21% | |
Price vs 52 Week Low | 112.50% | |
Range | 0.1808 | |
Gap Up/Down | -0.0100 |
Fundamentals | ||
Market Capitalization (Mln) | 291 | |
EBIDTA | 6,815,000 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 8.0000 | |
Book Value | 0.8820 | |
Earnings Per Share | -0.8400 | |
EPS Estimate Current Quarter | 0.0000 | |
EPS Estimate Next Quarter | -0.0200 | |
EPS Estimate Current Year | -0.0100 | |
EPS Estimate Next Year | 0.2000 | |
Diluted EPS (TTM) | -0.8400 | |
Revenues | ||
Profit Marging | -0.2493 | |
Operating Marging (TTM) | 0.0275 | |
Return on asset (TTM) | -0.0123 | |
Return on equity (TTM) | -1.5876 | |
Revenue TTM | 80,754,000 | |
Revenue per share TTM | 3.1590 | |
Quarterly Revenue Growth (YOY) | 0.8750 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | 51,999,000 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 117.6471 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 4.0028 | |
Revenue Enterprise Value | 2.9481 | |
EBITDA Enterprise Value | -213.5159 | |
Shares | ||
Shares Outstanding | 52,374,700 | |
Shares Float | 8,062,585 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.01 | |
Insider (%) | 5.97 | |
Institutions (%) | 93.11 |
06/26 21:40 EST - accesswire.com
SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alimera Sciences, Inc. ("Alimera" or the "Company") (NASDAQ:ALIM), in connection with its acquisition by ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Under the merger agreement, the Company's shareholders will receive $5.50per share in cash at closing and one non-tradable contingent value right ("CVR") to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.
SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alimera Sciences, Inc. ("Alimera" or the "Company") (NASDAQ:ALIM), in connection with its acquisition by ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Under the merger agreement, the Company's shareholders will receive $5.50per share in cash at closing and one non-tradable contingent value right ("CVR") to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.
06/25 12:05 EST - zacks.com
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
Alimera (ALIM) is set to be acquired by ANI Pharmaceuticals for approximately $381 million in upfront consideration. The transaction is expected to close in the third quarter of 2024.
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
Alimera (ALIM) is set to be acquired by ANI Pharmaceuticals for approximately $381 million in upfront consideration. The transaction is expected to close in the third quarter of 2024.
06/24 13:06 EST - benzinga.com
Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 300 points on Monday.
Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 300 points on Monday.
06/24 12:39 EST - prnewswire.com
Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public Shareholders
MILWAUKEE , June 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Alimera (Nasdaq: ALIM) for possible breaches of fiduciary duty and other violations of law in its transaction with ANI Pharmaceuticals. Click here to learn how to join the https://www.ademilaw.com/case/alimera-sciences-inc or call Guri Ademi toll-free at 866-264-3995.
Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public Shareholders
MILWAUKEE , June 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Alimera (Nasdaq: ALIM) for possible breaches of fiduciary duty and other violations of law in its transaction with ANI Pharmaceuticals. Click here to learn how to join the https://www.ademilaw.com/case/alimera-sciences-inc or call Guri Ademi toll-free at 866-264-3995.
06/24 11:31 EST - investorplace.com
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
Alimera Sciences (NASDAQ: ALIM ) stock is rocketing higher on Monday after the pharmaceutical company announced an acquisition deal with ANI Pharmaceuticals (NASDAQ: ANIP ). This agreement will have ANI Pharmaceuticals paying $5.50 per share for ALIM stock.
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
Alimera Sciences (NASDAQ: ALIM ) stock is rocketing higher on Monday after the pharmaceutical company announced an acquisition deal with ANI Pharmaceuticals (NASDAQ: ANIP ). This agreement will have ANI Pharmaceuticals paying $5.50 per share for ALIM stock.
06/24 09:21 EST - globenewswire.com
ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals
MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) to ANI Pharmaceuticals (“ANI”) for $5.50 per share in cash, plus a contingent value right (CVR) of $0.50 per share upon the achievement of certain net revenue milestones.
ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals
MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) to ANI Pharmaceuticals (“ANI”) for $5.50 per share in cash, plus a contingent value right (CVR) of $0.50 per share upon the achievement of certain net revenue milestones.
06/24 08:08 EST - invezz.com
Alimera Sciences stock rallies 75% on ANI Pharmaceuticals deal
Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. ANI shares are roughly flat at writing.
Alimera Sciences stock rallies 75% on ANI Pharmaceuticals deal
Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. ANI shares are roughly flat at writing.
06/24 07:54 EST - businesswire.com
ALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alimera Sciences, Inc. (NASDAQ: ALIM) to ANI Pharmaceuticals, Inc. for $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027 is fair to Alimera shareholders. Halper Sadeh encourages Alimera shareholders to click here to learn more about t.
ALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alimera Sciences, Inc. (NASDAQ: ALIM) to ANI Pharmaceuticals, Inc. for $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027 is fair to Alimera shareholders. Halper Sadeh encourages Alimera shareholders to click here to learn more about t.
06/04 16:30 EST - globenewswire.com
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”) approved, on May 22, 2024 (the “Grant Date”), inducement awards consisting of stock options under the Alimera Sciences, Inc. 2024 Equity Inducement Plan to persons who were not previously employees or who rejoined the Company following a bona fide period of non-employment, as an inducement material to each such new or re-hired employee's employment (collectively, the “Inducement Awards”).
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”) approved, on May 22, 2024 (the “Grant Date”), inducement awards consisting of stock options under the Alimera Sciences, Inc. 2024 Equity Inducement Plan to persons who were not previously employees or who rejoined the Company following a bona fide period of non-employment, as an inducement material to each such new or re-hired employee's employment (collectively, the “Inducement Awards”).
05/14 13:40 EST - seekingalpha.com
Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q1 2024 Earnings Conference Call May 14, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President and Chief Executive Officer Elliot Maltz - Chief Financial Officer Todd Wood - President U.S. Operations Philip Ashman - President, International Operations Conference Call Participants Chase Knickerbocker - Craig-Hallum Yi Chen - H.C. Wainwright & Company Naz Rahman - Maxim Group James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by.
Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q1 2024 Earnings Conference Call May 14, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President and Chief Executive Officer Elliot Maltz - Chief Financial Officer Todd Wood - President U.S. Operations Philip Ashman - President, International Operations Conference Call Participants Chase Knickerbocker - Craig-Hallum Yi Chen - H.C. Wainwright & Company Naz Rahman - Maxim Group James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by.
05/14 09:41 EST - zacks.com
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.71 per share a year ago.
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.71 per share a year ago.
05/14 07:30 EST - globenewswire.com
Alimera Sciences Reports First Quarter 2024 Results
ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
Alimera Sciences Reports First Quarter 2024 Results
ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
03/19 08:00 EST - globenewswire.com
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy
03/13 09:01 EST - zacks.com
New Strong Sell Stocks for March 13th
ASLE, ALIM and CADE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2024.
New Strong Sell Stocks for March 13th
ASLE, ALIM and CADE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2024.
03/07 12:39 EST - seekingalpha.com
Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q4 2023 Earnings Conference Call March 7, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President & Chief Executive Officer Elliot Maltz - Chief Financial Officer Todd Wood - President, U.S. Operations Conference Call Participants Alex Nowak - Craig-Hallum Capital James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Fourth Quarter and Fiscal Year 2023 Financial Results and Corporate Update Conference Call.
Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q4 2023 Earnings Conference Call March 7, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President & Chief Executive Officer Elliot Maltz - Chief Financial Officer Todd Wood - President, U.S. Operations Conference Call Participants Alex Nowak - Craig-Hallum Capital James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Fourth Quarter and Fiscal Year 2023 Financial Results and Corporate Update Conference Call.
03/07 10:01 EST - zacks.com
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.54 per share a year ago.
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.54 per share a year ago.
03/07 07:30 EST - globenewswire.com
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance
02/08 08:00 EST - globenewswire.com
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME) NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME)
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME) NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME)
01/02 08:00 EST - globenewswire.com
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that Elliot Maltz, C.P.A., has been named Chief Financial Officer effective immediately.
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that Elliot Maltz, C.P.A., has been named Chief Financial Officer effective immediately.
12/12 07:30 EST - globenewswire.com
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately.
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately.